AN OPEN-LABEL PHASE1/1B STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF JNJ-73841937 (LAZERTINIB), A THIRD GENERATION EGFR-TKI, AS MONOTHERAPY OR IN CONBINATIONS WITH JNJ-61186372, A HUMAN BISPECIFIC EGFR AND CMET ANTIOBODY IN PARTICIPANTS WITH ADVANCED NON-SMAILL CELL LUNG CANCER